이창열 (KRIBB, Massachusetts General Hospital Research Institute)

한빛사논문

조회107

이창열Chang Yeol Lee

KRIBB, Massachusetts General Hospital Research Institute

Nat. Commun., 25 July 2024 | https://doi.org/10.1038/s41467-024-50588-3 Empowering the on-site detection of nucleic acids by integrating CRISPR and digital signal processing

Chang Yeol Lee ^1,2,3,10, Hyunho Kim ^1,2,10, Ismail Degani ^1,4,10, Hanna Lee ¹, Angel Sandoval¹, Yoonho Nam^1,5, Madeleine Pascavis ^1,6, Hyun Gyu Park ⁵, Thomas Randall ⁷, Amy Ly ⁸, Cesar M. Castro^1,9,*& Hakho Lee ^1,2,*

¹Center for Systems Biology, Massachusetts General Hospital Research Institute, Boston, MA, USA.
²Department of Radiology, Massachusetts General Hospital,HarvardMedical School, Boston,MA, USA.
³Bionanotechnology ResearchCenter, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Republic of Korea.
⁴Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
⁵Department of Chemical and Biomolecular Engineering (BK21 Four), Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Yuseonggu, Daejeon 34141, Republic of Korea.
⁶CaNCURE program, College of Science, Northeastern University, Boston, MA, USA.
⁷Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, USA.
⁸Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston,MA,USA.
⁹Department of Medicine,Massachusetts General Hospital, HarvardMedical School, Boston,MA, USA.
¹⁰These authors contributed equally: Chang Yeol Lee, Hyunho Kim, Ismail Degani.

^*Corresponding authors: correspondence to Cesar M. Castro or Hakho Lee

Abstract

Addressing the global disparity in cancer care necessitates the development of rapid and affordable nucleic acid (NA) testing technologies. This need is particularly critical for cervical cancer, where molecular detection of human papillomavirus (HPV) has emerged as an accurate screening method. However, implementing this transition in low- and middle-income countries has been challenging due to the high costs and centralized facilities required for current NA tests. Here, we present CreDiT (CRISPR Enhanced Digital Testing) for on-site NA detection. The CreDiT platform integrates i) a one-pot CRISPR strategy that simultaneously amplifies both target NAs and analytical signals and ii) a robust fluorescent detection based on digital communication (encoding/decoding) technology. These features enable a rapid assay (<35 minutes) in a single streamlined workflow. We demonstrate the sensitive detection of cell-derived HPV DNA targets down to single copies and accurate identification of HPV types in clinical cervical brushing specimens (n = 121).

논문정보

형식Research article
게재일2024년 07월 (BRIC 등록일 2024-08-14)
연구진국내+국외 연구진
분야 바이오·의료융합 > 바이오센싱 및 나노바이오물질

댓글 작성 로그인

CV 열람하기

연락처 보기